Author

Armel Maurice Cheugoua-Zanetsie

Observed names: M. Cheugoua-Zanetsie, Maurice Cheugoua-Zanetsie

Institutions: Inserm, Université Paris-Saclay, Institut Gustave Roussy, Centre de recherche en Epidémiologie et Santé des Populations

Observed institutions: Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer, Centre de recherche en Epidémiologie et Santé des Populations

ORCID: 0000-0002-9447-4631

Observed ORCID: 0000-0002-9447-4631

OpenAlex ID: A5074067928

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

2021 · Claire Petit, Benjamin Lacas, et al. · The Lancet Oncology · 112

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

2023 · Matthieu Faron, Maurice Cheugoua-Zanetsie, et al. · Journal of Clinical Oncology · 43

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

2021 · Matthieu Faron, Armel Maurice Cheugoua-Zanetsie, et al. · European Journal of Cancer · 13

857O MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)

2023 · P. Blanchard, M. Cheugoua-Zanetsie, et al. · Annals of Oncology · 7

Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy

2025 · Nicolas Cabrit, Maurice Cheugoua-Zanetsie, et al. · European Journal of Cancer · 5

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.

2021 · Matthieu Faron, Armel Maurice Cheugoua-Zanetsie, et al. · Journal of Clinical Oncology · 1

SO-5 Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials

2022 · N. Cabrit, M. Faron, et al. · Annals of Oncology

SO-4 Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma

2022 · M. Faron, M. Cheugoua-Zanetsie, et al. · Annals of Oncology

Works count: 9

Citation count: 224

H-index: 5

I10-index: 4